Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Abstract: A method is disclosed for making a high-silica zeolite having an FAU framework structure. The method includes: (1) preparing a reaction mixture comprising: (a) a source of silica; (b) a source of alumina; (c) a source of an alkali or alkaline earth metal cation; (d) an organic structure directing agent containing at least one cation selected from a 1,2-dimethyl-3-(3-methylbenzyl) imidazolium cation, a 1-ethyl-3-methylimidazolium cation, and a 1-butyl-3-methylimidazolium cation; (e) a source of hydroxide ions; and (f) water; (2) heating the reaction mixture under crystallization conditions including a temperature of from 80° C. to 200° C. for a time sufficient to form crystals of the high-silica zeolite; and (3) recovering at least a portion of the high-silica zeolite from step (2).

Abstract: Implementations of the present application relate to caller previews for video calls. In some implementations, a method includes sending, by a caller device, a call request to a callee device and determining an identifier associated with the callee device. The method determines whether the identifier is associated with an address book of the caller device, and/or is in an outgoing call record of the caller device. An acknowledgment is received from callee device, and, upon receipt of the acknowledgment, a connection is established with the callee device. Based on determining that the identifier is associated with the address book and/or in the outgoing call record, at least a portion of a caller video is transmitted over the connection with the callee device. The caller video is transmitted prior to receipt of an acceptance of the call request from the callee device.

Abstract: Implementations of the present application relate to caller previews for video calls. In some implementations, a method includes sending, by a caller device, a call request to a callee device and determining an identifier associated with the callee device. The method determines whether the identifier is associated with an address book of the caller device, and/or is in an outgoing call record of the caller device. An acknowledgment is received from callee device, and, upon receipt of the acknowledgment, a connection is established with the callee device. Based on determining that the identifier is associated with the address book and/or in the outgoing call record, at least a portion of a caller video is transmitted over the connection with the callee device. The caller video is transmitted prior to receipt of an acceptance of the call request from the callee device.

Abstract: Implementations of the present application relate to caller previews for video calls. In some implementations, a method includes sending, by a caller device, a call request to a callee device and determining an identifier associated with the callee device. The method determines whether the identifier is associated with an address book of the caller device, and/or is in an outgoing call record of the caller device. An acknowledgment is received from callee device, and, upon receipt of the acknowledgment, a connection is established with the callee device. Based on determining that the identifier is associated with the address book and/or in the outgoing call record, at least a portion of a caller video is transmitted over the connection with the callee device. The caller video is transmitted prior to receipt of an acceptance of the call request from the callee device.

Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.

Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.

Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.

Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.